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ABSTRACT 
 
The reconstruction of osseous mandibular defects remains a significant challenge. The use of 
autologous bone for mandibular reconstruction is associated with numerous limitations, and 
alternatives to autologous bone would provide significant benefits for patients. The aim of this 
study was to evaluate and compare binary application of recombinant human bone 
morphogenetic protein 7 (rhBMP-7) and recombinant human transforming growth factor  
(rhTGF-3) to solo application of recombinant human bone morphogenetic protein 7 (rhBMP-7) 
in full-thickness mandibular defects in the non-human primate Papio ursinus. In four baboons, a 
2.5cm segmental defect was created in the mandible and stabilized with a 2.7mm titanium 
reconstruction plate. Two defects were implanted with rhBMP-7 solo, and the other two with 
binary application rhBMP-7 and rhTGF-3 at a ratio of 20:1. All four baboons were euthanazed 
at 180 days post implantation. All four specimens were radiographed prior to sectioning. Tissue 
processing and histomorphometry were done on the undecalcified sections prepared from the 
harvested mandible specimens. In all defects bone regeneration re-established bony continuity at 
six months. The mean area of the regenerate was 336 ± 107.5 mm
2 
(range 229-444.7) in the solo 
specimens, and 312 ± 63.5mm
2
 (range 249-376.6) in the binary specimens. Radiographic 
examination confirmed complete bone healing in all defects but variable restitution of defect 
volume. The regenerated bone had a trabecular pattern consistent with mature mandibular bone 
and the defect interfaces were indiscernible.  Due to the small sample size no performance 
advantage could be identified between the two treatment groups. These results confirm that 
successful bone regeneration by tissue induction in surgically created mandibular defects can be 
achieved with osteogenic proteins of the transforming growth factor- superfamily.  
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1  INTRODUCTION 
1.1 Mandibular defects 
 
The reconstruction of osseous mandibular defects remains a significant challenge for 
reconstructive surgeons. The complex anatomy of the mandible and the harsh environment in 
which a reconstruction is needed magnify the complexities of the task.
1
 The goal of mandibular 
reconstruction is to restore mandibular continuity and morphology to allow functional 
rehabilitation with osseointegrated dental implants. Functional loading of the repaired mandible 
demands that the regenerated bone is of sufficient height, width and strength to withstand the 
forces of mastication to which it is exposed.  Autogenous bone grafts (either free or pedicled) are 
the most effective choice for mandibular reconstruction.
2, 3 
 Free grafts can be either cortical, 
cancellous or corticocancellous blocks, and can be obtained from local, regional or distant sites 
depending on the size of the defect to be reconstructed. The most used donor site for bone 
grafting is the anterior and posterior ilium, which provides large volumes of corticocancellous 
bone. Costochondral grafts are required to provide for temporomandibular joint replacement. 
Less commonly used alternatives include cranial and tibial grafts.
3  
Microvascular free flaps 
(either from the fibula, iliac crest, scapula or radius) have the advantage of having their own 
blood supply independent of the local tissue bed.
3  
Although autogenous bone graft provides an 
effective reconstructive option, its use is associated with numerous draw backs including donor 
site morbidity, costs of extended operative time, and difficulty of adapting the graft to 
appropriate shape and contour. In addition, in young patients, insufficient bone at the donor sites 
may preclude successful reconstruction.
3 
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It has therefore been the hope of reconstructive surgeons to regenerate bone without harvesting 
autogenous bone, by using homologous (allograft) and heterogenous grafts (xenograft). None of 
these materials have equalled the outcomes of autogenous grafts.
3 
In light of these challenges 
focus has shifted to investigate alternatives for effective bone tissue regeneration to rehabilitate 
mandibular and other bony defects. Improved understanding of the biology of bone grafting, and 
biotechnological advancements have provided reconstructive alternatives to autologous bone for 
mandibular reconstruction.
1
 
 
1.2 The induction of bone formation 
 
Bone formation is initiated prenatally and continues throughout development. This process is 
referred to as osteogenesis and involves the synthesis of new bone matrix by cells called 
osteoblasts.
4
 Osteogenesis may occur either by intramembranous or endochondral ossification. In 
the former, bone is formed in primitive mesenchyme. In endochondral ossification, bone 
formation occurs over a precursor of cartilage. In post natal life, this process is recapitulated 
during fracture healing.
4
 The cells involved in bone formation and remodelling are osteoblasts, 
osteoclasts and osteocytes. Numerous growth factors play important roles during embryonic 
formation of bone: bone morphogenetic proteins (BMPs), transforming growth factor-TGF-, 
growth and differentiation factors (GDF) and cartilage derived morphogenetic proteins 
(CDMP).
4
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Marshall Urist’s seminal work confirmed that demineralized bone matrix when implanted in 
rabbits, rats, mice, guinea pigs and humans, induced formation of vital cellular bone.
5
 He 
surmised that this induction was due to the activity of new morphogens which he termed bone 
morphogenetic protein (BMP).
5, 6
 Sampath and Reddi demonstrated that the putative 
osteoinductive proteins could be dissociatively extracted from the demineralized bone matrix 
using chaotropic agents.
7, 8
 Demineralized bone matrix subjected to dissociative extraction, 
yields two components: a protein extract, and an insoluble collagenous matrix or residue.
7, 8
 
After chaotropic extraction, the osteoinductive capacity of the resultant insoluble collagenous 
bone matrix (ICBM) is lost.
7, 8 
 However, reconstitution of the extracted soluble signals with the 
residual inactive collagenous matrix resulted in the restoration of osteoinductive activity.
7, 8  
This 
bone-inductive potential is not species specific and osteogenic proteins from different species 
induce bone formation in another species when reconstituted with their homologous insoluble 
collagenous bone matrix.
7, 8 
 
The isolation of putative osteogenic tissues within the bone matrix proved to be a challenge 
given the small quantity of proteins bound to the extracellular matrix of bone.
9
 The process of 
purification requires solubilisation of bone inductive fractions from the bone matrix. Increasingly 
refined purification schemes were instrumental to purify to homogeneity naturally-derived 
BMPs.
10
 BMPs could be purified in sufficient quantity and purity to obtain amino acid sequence 
information.
10
 From this information, full-length complementary DNA clones were isolated 
encoding the human equivalent of several recombinant human BMPs (rhBMP).
10 
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1.3 The osteogenic proteins of the transforming growth factor- supergene family  
 
The transforming growth factor- β (TGF-β) supergene family is a large family of structurally 
related cell regulatory proteins that are pleiotropic peptides that control cellular proliferation, 
differentiation and a plethora of other functions in different cell types.
11-16
 BMPs are members of 
the TGF-β supergene family that also include the three mammalian TGF- isoforms, the 
amphibian TGF-β5 isoform, GDF and CDMPs.
11-16
 BMPs are critical morphogens in bone 
induction and regeneration. There are at least 20 BMPs which have been identified, characterized 
and cloned.
3, 14-17
 The induction of bone formation is conferred by these osteogenic molecular 
signals collectively referred to as BMPs or osteogenic proteins (OPs). The BMPs are involved in 
the formation of bone and cartilage during embryonic development, and are also known to be 
involved in postnatal osteogenesis. Moreover, BMPs are involved in axial growth, hard tissue 
development and repair, tooth morphogenesis, and neural development.
18
  Many members of the 
TGF- superfamily possess the unique ability to induce bone formation not only orthotopically, 
but also heterotopically, recapitulating embryonic development.
2-4, 18
 
 
 
BMP-2 and 7 have been produced by recombinant DNA technology using mammalian cells.
10, 16 
Cloned rhBMPs have been shown to singly induce bone formation after implantation in 
heterotopic sites in murine models. rhBMPs can induce in a dose dependant fashion 
mesenchymal cell chemotaxis and infiltration, differentiation of the cells into chondrocytes, 
chondrolysis, formation of bone with bone marrow elements, and ultimately normal remodeling 
of the bone.
10
 At different concentrations of the rhBMPs, various amounts of cartilage and bone 
14 
 
can be formed, with the cartilage always being replaced by bone marrow after vascular invasion. 
The larger the dose of rhBMPs, the earlier osteoinduction occurs, and the more significant the 
amount of bone formed in preclinical studies in a range of animal models.
19-21
 
 
Thus they can be referred to as differentiation and/or inducing factors. Ultimately, as 
differentiation factors they cause the host to induce bone formation which functions and 
remodels in a way appropriate for the environment into which it takes place. Despite the fact that 
heterotopic implantation of single rhBMPs induce bone differentiation, there is a cascade of 
events at molecular and cellular levels which involves the expression of different BMPs and 
other growth factors in a particular spatial and temporal sequence culminating in the formation of 
bone tissue and bone marrow organs.
11, 18
   
 
1.4 Delivery system 
 
Bone tissue engineering requires a scaffold to initiate and spatially regulate the process of 
osteogenesis.
11, 18
 The use of biomimetic matrices controlling the expression of the soluble 
molecular signals provides one of the three key components for bone regeneration. The use of 
insoluble collagenous bone matrix (ICBM) and other collagen-based materials provide a 
substratum for the functional expression of BMPs.  This carrier is the inactive and insoluble 
residue obtained after dissociative extraction of the bone matrix. It is the reconstitution of the 
soluble signal (BMPs) with this insoluble signal or substratum of the bone matrix that 
15 
 
demonstrated the critical role of the carrier for the induction of bone formation.
7  
 Inactive ICBM 
has also been shown to play a role in cell recruitment, attachment and proliferation of 
mesenchymal cells. The organic collagenous matrices however, have operative limitations which 
include no structural support, immunogenic response, and potential transmission of viral 
antigens. These drawbacks have motivated scientists to search for alternative substrata to deliver 
the biological activity of rhBMPs.
22, 23
 
 
1.5 Synergy  
 
Synergy is the combination of two products to produce a result greater than the sum of their 
individual effects. Serendipitously, Ripamonti et al. in 1997, discovered that TGF-1 and BMP-7 
synergize to rapidly promote the induction of bone formation.
24, 25
 Binary application of TGF-1 
and BMP-7 induce a several fold increase in bone volume as compared to solo use of either 
protein heterotopically.
24, 25
 It was shown that significant angiogenesis characterizes the 
synergistic induction of bone formation which thus enables a faster induction of bone formation. 
It has been hypothesized that TGF-may regulate the expression of different BMPs, acting 
upstream of the BMPs and may induce the induction of bone by expressing selected BMP gene 
products eventually resulting in the induction of bone formation.
24, 25  
This phenomenon may be 
exploited to improve clinical performance in human patients. 
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1.6 Preclinical and clinical application of BMPs and TGF-
 
Tissue engineering is defined as the construction of new tissues by regeneration for replacement 
based on principles of developmental and molecular biology.
26  
Bone regeneration in preclinical 
and clinical contexts requires a number of key components which includes an insoluble signal or 
substratum, an inductive molecular signal, and responding host cells capable of differentiating 
into osteoblasts.
12-14 
 It is this fundamental understanding of bone induction that has become the 
basis of hard tissue regeneration.  
 
The theoretical potential of BMPs to be deployed therapeutically has been tested in several 
animal models. Critical size bone defects were created in the mandible of animal models into 
which rhBMP-2 and rhBMP-7 were implanted.
19-21
 The application of recombinant or natively 
sourced BMPs have been found to successfully restore critical sized defects in rats, pigs, rabbits, 
dogs, sheep, monkeys, and baboons.
19-21 
Combined use of rhBMP-2 and rhTGF-induce bone 
formation in heterotopic sites in mice.
27
 Comparative histomorphometry of iliac crest biopsy 
specimens from humans and Papio ursinus demonstrate a remarkable degree of similarity 
between the two.
28
 This data indicates that the adult baboon is ideally suited for comparative 
bone physiology and repair with relevance to humans.
28 
 Preclinical studies in the non-human 
primate Papio ursinus, have shown that a single application of the rhBMP-7 results in complete 
regeneration of both craniofacial and periodontal defects. rhTGF- combined with allogeneic 
ICBM induces regeneration of segmental mandibular defects as evaluated 30 days post 
implantation in Papio ursinus, and induces periodontal tissue regeneration. 
18, 23, 25, 29-31
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Exploitation of bone induction was first attempted in humans with allogeneic demineralized bone 
matrix to reconstruct congenital craniofacial defects and mandibular defects. These trials 
determined success based on radiographic findings of bone formation with no histological 
evidence confirming the induction of bone formation.
32, 33 
 
 
Reports of the use of BMPs in the craniofacial region are appearing on a regular basis. BMPs 
have been used in sinus lifting, mandibular osteotomies and reconstruction.
34-38
 Bone induction 
by rhBMP-2 in sinus augmentation was found to be an effective inductor of bone formation but 
required massive doses and incurred significant costs.
26, 31, 39, 40
  
 
The first reported attempt to reconstruct a defect of the maxillofacial skeleton with naturally 
derived BMPs was done by Moghadam et al. in 2001. Their positive assessment of the outcome 
is not supported by critical assessment of the radiographic evidence which did not reveal 
ossification in the defect even nine months after implantation of BMPs.
41 
The first series of 
patients to provide histological evidence of bone induction in mandibular segmental defects in 
humans treated with naturally derived BMPs was done by Ferretti and Ripamonti.
1
 Thirteen 
patients were enrolled in the trial, comparing autogenous iliac crest graft in seven patients, to six 
patients receiving an osteogenic device human demineralized bone matrix as a carrier for highly 
purified naturally-derived bovine BMPs. Histological analysis showed that the osteogenic 
devices induced bone in only two of six patients treated, which provided valuable insights for the 
use of BMPs in human mandibular defects, necessitating the need for further clinical research.
1
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Warnke et al. attempted the growth of a custom bone transplant in the latissimus dorsi of a 
human patient using rhBMP-7, for transplantation into a mandibular defect.
 
Seven months after 
transplantation, the graft became exposed and secondarily infected leading to its failure.
42, 43 
Radiographic examination of the mandible did not support the conclusion of successful and 
clinically significant bone induction. Despite this failure the authors felt it was a technique that 
warranted further investigation. Heliotis et al. also prefabricated a hydroxyapatite/BMP-7 
implant in a vascularized pedicled bone flap in the human chest for hemimandible 
reconstruction. Despite histological evidence of osteogenesis within the hydroxyapatite carrier, 
transplantation of the pedicled bone flap to the mandibular defect was not successful.
44
 
 
Other studies conducted to investigate the use of BMPs in human subjects with mandibular 
continuity defects have found sparse areas of bone production and poor radiographic correlation 
to support the claim of osseous healing.
41, 46-49
 Herford reported his experiences of mandibular 
reconstruction with rhBMP-2 in an absorbable collagen sponge carrier.
47
 Once again the paper 
concluded that the technique worked in all cases and advocated its use in maxillofacial skeletal 
defects, however critical review of the radiographs accompanying his publication cannot support 
this conclusion (Figure 1).  
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Figure 1: Panoramic radiograph post implantation with BMP-2 in mandibular defect. Objective 
assessment shows the defect bone density and architecture is of inferior quality to that of the 
adjacent mandible. 
47 
 
BMP-2 enjoyed a surge in popularity for spinal fusion. This enthusiasm was based on a series of 
publications from several authors detailing the clinical success associated with the use of BMP-2. 
Subsequently, Eugene Carragee published a scathing review of the data associated with the 
above mentioned trials to conclude that in fact the use of BMP-2 for spinal fusion was associated 
with numerous complications.
50
  
 
Translating the successful preclinical outcomes from non-human primates into clinical context 
has proven to be a formidable task. In marked contrast to preclinical data, supraphysiological 
doses of a single recombinant gene product are required to induce clinically unacceptable 
amounts of bone formation by induction, thus incurring high costs while failing to achieve the 
20 
 
outcomes of autogenous bone grafts.
26, 39, 40 
 It is clear that the promise of therapeutic bone tissue 
engineering remains elusive.
50
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2 AIM 
 
The aim of this study is to evaluate and compare binary application of rhBMP-7 and rhTGF-3, 
to the single application of rhBMP-7 in full-thickness mandibular defects in the non-human 
primate Papio ursinus. This investigation will assess whether clinically significant 
osteoinduction by rhBMP-7 singly and in combination with rhTGF-3, can be obtained in 
surgically created mandibular defects. Success in this binary application could lead to the clinical 
application of rhBMPs and rhTGF-3 in human subjects for tissue regeneration and may provide 
an alternative therapeutic option for human bone tissue engineering.    
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3 MATERIALS AND METHODS  
3.1 Experimental animal selection 
 
Ethics approval was obtained from the Animal Ethics Committee, University of the 
Witwatersrand, Johannesburg, clearance code AESC 2006715. Four clinically healthy adult 
Chacma baboons (Papio ursinus) with normal hematological and biochemical profiles 
51
 and 
skeletal maturity confirmed by radiograph evidence of closure of the distal epiphyseal plates of 
radius and ulna were selected from the primate colony of the University of Witwatersrand, 
Johannesburg.
13, 30 
 Non-human primates were housed at the Central Animal Services of the 
University, Medical School in compliance with the National Code for Animal Use in Research 
and Education in South Africa.
52
  
 
3.2 Morphogens  
3.2.1 rhBMP-7 
 
Mature rhBMP-7 is a gylcosolated 36kDa homodimer of 139 amino acid residue chains. rhBMP-
7 prepared as previously described by Sampath et al., was kindly supplied by Stryker Biotech 
(Hopkinton, Massachusetts, U.S.A.).
53
 It was supplied in 12 sterile vials each containing 1g of 
bovine insoluble collagenous bone matrix preloaded with 2.5mg rhBMP-7.  
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3.2.2 Transforming Growth Factor- 
 
Mature recombinant rhTFG-a gylcosolated 25kDa homodimer with a C-terminal domain of 
112 amino acids with nine cysteine residues, was obtained from Novartis Pharma AG (Basel, 
Switzerland) and supplied as a stock solution of rhTGF-3 9.37mg per mL of diluent. This was 
further diluted with 5mmol acetic acid to obtain a concentration of 1µg rhTGF-3 per µl of 
diluent. 
 
3.3 Preparation of implants 
 
Twelve vials each containing 2.5mg rhBMP-7 and 1g bovine insoluble collagenous bone matrix, 
were provided for implantation. To six of the vials was added 125µl of the diluted rhTGF-3 
solution for a final dose of 125µg of rhTGF-3 per vial to obtain a 20:1 ratio rhBMP-7: rhTGF-
3. This has been the ratio with the highest biological activity when implanted in heterotopic 
sites of Papio ursinus.
22
 The other six vials were used for implantation of rhBMP-7 solo.  
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3.4 Surgery  
3.4.1 General anaesthesia 
Baboons were operated under general anaesthesia induced with a mixture of Ketamine 
(100mg/ml, Bayer, India (Pty) Ltd) at a dose volume of 5mg/kg, and Midazolam (5mg/ml, Roche 
Prod. (Pty) Ltd) at a dose of 0.25mg/kg given intramuscularly. Oro-tracheal intubation was done 
to provide inhalation of Isoflurane (Forane 1.5% 250mL, Piramal Critical Care, Inc, Bethlehem 
U.S.A.) and oxygen for maintenance. Buprenorphine Hydrochloride (Temgesic 0.3mg/ml, RB 
Pharmaceutics Ltd, United Kingdom) at a dose of 0.01 - 0.03mg/kg and Meloxicam (Mobic, 
10mg/ml, Ingelham Pharm. (Pty) Ltd) at a dose of 0.2-0.3mg/kg were given subcutaneously for 
analgesia. All baboons were given an intramuscular dose of oxytetracycline (Phenix, Peni LA, 
Phenix S.A. (Pty) Ltd 1ml/10kg) intraoperatively. Doxapram Hydrochloride (Dopram 20mg/ml, 
Amdipharm Mercury Ltd. UK) was used as reversal agent at a dose of 0.5-1mg/kg intravenously 
in all cases. Postoperatively Carpofen (Novox 100mg/tab, Impax Labs, U.S.A.) was given at a 
dose of 4mg/kg per os, crushed in banana, as an anti-inflammatory.  
 
3.4.2 Extractions 
All baboons had extractions of teeth on the right side of the mandible and maxilla from the right 
canines posteriorly. Eight weeks thereafter, the baboons were returned to theatre and the 
operative sites inspected for complete healing of the oral wound in order to avoid contamination 
when implanting the osteogenic devices.  
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3.4.3 Preparation of mandible defect 
The skin over the right hemimandible was shaved and the right hemimandible exposed via an 
extra oral submandibular approach. A 2.7mm titanium reconstruction plate (Biomet 
Microfixation, Jacksonville U.S.A.) was then pre-bent against the exposed mandible to ensure 
accurate contouring of the plate and maintenance of occlusion post-resection. A 2.5cm defect 
was marked in the right body of the mandible using a bone saw and the pre-bent plate secured 
with titanium screws to proximal and distal segments of the mandible for immobilization.The 
screws were then removed, the defect completed and the plate replaced (Figure 2).   
 
 
Figure 2: Lateral view of right mandible showing surgically created defect with screw holes on 
either side. 
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3.4.4 Implantation protocol of device into mandible defect 
 
The osteoinductive device was moistened with sterile saline to form a paste. The paste was 
inserted into the defect (Figure 3) and primary closure of soft tissues ensured that the implant 
was maintained within the defect. Two of the baboons each received three vials of prepared 
device for a total of 3g of ICBM and 7.5mg rhBMP-7. The other two baboons received three 
vials each equivalent to 3g delivery and a total dose of 7.5mg rhBMP-7 and 375µg rhTGF-3 
(ratio 20:1). Postoperatively the baboons were fed an all soft fruit and vegetable diet with 
Mealie-meal based porridge fortified with protein, vitamin and mineral powder for six weeks, 
thereafter returning to normal solid foods. The baboons were monitored daily for their ability to 
self-care and feed, and surgical wounds were examined for signs of infection.  
 
Figure 3: Defect implanted with saline moistened with osteoinductive device 
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3.4.5 Euthanasia and Tissue harvest 
 
The baboons were anaesthetized 180 days post implantation, and the right and left carotid 
arteries were exposed via a midline incision in the neck. The carotids were transected and 
cannulated to allow perfusion of the mandible with 1 litre of saline in each carotid. The animals 
were thus euthanazed with Nembutal sodium (Pentobarbital 50mg/mL, Lundbeck Inc. Deerfield, 
IL U.S.A.) following which further perfusion of the carotids was done with 1 litre of formalin in 
each carotid. The hemi-mandibles were resected and skeletonised for radiographic imaging and 
histological processing. The defect and 1cm of normal bone was included in the final specimen. 
 
3.5 Analytical procedures 
3.5.1 Histomorphometry 
 
Undecalcified tissues were processed according to the method of Donath and Breuner with minor 
modifications.
53
 Briefly the tissues were processed in ascending grades of ethanol in an 
automatic tissue processor (Tissue-Tek, V.I.P.; Miles Inc, Elkhart, USA), under pressure vacuum 
cycles. Samples were infiltrated with ascending concentration of Technovit 7200 VLC (Heraeus 
Kulzer GmbH, Wehrheim, Germany) and embedded in a fresh solution of the same resin. 
Undecalcified sections were then ground and polished to m and stained with a modified 
Goldner’s trichrome. All sample preparation was performed using the EXAKT precision cutting 
and grinding system (EXAKT Apparatebau, Nordestedt, Hamburg, Germany).  
28 
 
Digital images were acquired using the Olympus BX16 microscope with built-in camera. 
Quantification of regenerated tissue was carried out using Stream Essentials software. Stream 
Essentials consists of four separate units including Olympus UPS, Microscope AX70, free 
standing control unit, a camera and associated software (Shinjuku Monolith, 3-1 Nishi-Shinjuku 
2-chrome, Tokyo, Japan). Stream Essentials can perform various functions which include 
acquiring an image through the microscope camera, performing measurements on that image, 
and exporting data to create a spreadsheet for analysis. Stream essentials software identifies bone 
based on the colour taken up by the program, distinction cannot be made between osteoid and 
mineralised tissue both of which take up the program similarly, therefore the amount of new 
bone formation includes both osteoid and mineralised tissue. 
 
Two sagittal sections were selected from each specimen for analysis. Each section included the 
entire defect and the interface with 1cm of intact mandible. A magnification factor of 10x was 
used for all specimens. The outline of the regenerated bone was selected to calculate the amount 
of regenerated bone formed within this outline (referred to as region of interest one (ROI 1)) 
(Figure 4). The original defect area was created by a quadrilateral whose sides are formed by the 
two interfaces and the superior and inferior borders by constructed lines joining the superior and 
the inferior ends of the interface lines. This was denoted as region of interest two (ROI 2). The 
total area of new bone was measured in mm
2
 and the percentage within each ROI was calculated.  
The regenerate as a percentage of ROI 2 reflects the percentage of the original defect area filled 
with mineralized bone, whereas the ROI 1 reflects the density of mineralized bone within the 
regenerate. All data captured was recorded in Microsoft Office Excel 2007 spreadsheet.   
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Figure 4: Photomicrograph of sagittal section through defect. Outlined in green is region of 
interest one (area of regenerate) and outlined in black is region of interest two (area of defect). 
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3.6.2 Radiographic assessment 
Although subjective, with critical examination, radiographs serve as an important tool to 
determine clinically significant osteoinduction, remodelling, and integration. It is more reliable 
than the histological examination. Clinically significant osteoinduction refers to the concept that 
the quality of regenerated bone by osteoinductive agents is adequate to be identified 
radiographically as normal bone (in radiodensity and trabecular pattern) and that the morphology 
of the reconstructed segment resembles that of the former skeletal segment.
54
 Although objective 
quantification of radiodensity and trabecular pattern on routine radiography is impossible it does 
provide an unequivocal overview of osseous regeneration in a defect.    
 
All four resected specimens were radiographed prior to sectioning. Specimens were radiographed 
from a lateral and occlusal view at kV 53 and mA 0.09. Radiographs were taken to assess the 
radiodensity of the regenerated bone and the trabecular pattern. Moreover, the size and 
morphology of the regenerate will be assessed as will the visibility of the osseous interfaces (as a 
guide to remodelling). With this evaluation the density of bone regenerate in the defect can be 
compared to the adjacent normal mandible.  
 
 
3.6.3 Statistical analysis 
Due to the limited number of animals as well as of each treatment modality, statistical analysis 
was not performed. 
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4 RESULTS 
4.1 Macroscopic examination of resected mandibles 
All four defects were filled with highly mineralized bone re-establishing continuity of the 
mandible. In specimen 005 implanted with rhBMP-7 solo (Figures 5a & b), there is no 
macroscopically evidence of the erstwhile defect, thus restitution of integrity has been achieved. 
In specimen 805 implanted with rhBMP-7 solo, regeneration was excessive and morphologically 
irregular along the inferior border (Figures 6a & b).  In the other two specimens (combined 
application of rhBMP-7 and rhTFG-3 at a ratio 20:1) there was uniform bone formation in all 
dimensions of the defect, blending imperceptibly to the adjacent margins of normal bone 
(Figures 7 & 8). Specimen 816 which was implanted with rhBMP-7 and rhTFG-3 had the 
lowest vertical height of new bone formed however the bucco-lingual dimension was equal to 
that of the adjacent bone (Figures 7a & b). Specimen 811 also implanted with rhBMP-7 and 
rhTFG-3 is shown in Figures 8a & b. This specimen shows complete restitution of morphology 
with bone covering the reconstruction plate. A sagittal section through the mandibular (Specimen 
005) reveals the density of the bone regenerate within the defect and the remodelling of the 
regenerate to normal architecture (Figure 9).  
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Figure 5a: Specimen 005 – rhBMP-7 solo. Lateral view of resected right hemimandible with 
reconstruction plate covered by bone regenerate with defect margins not apparent. Restitutio ad 
integrum of the mandibular defect.  
 
 
 
Figure 5b: Specimen 005 – rhBMP-7 solo. Occlusal view of right hemimandible showing 
restitution of bucco-lingual width in defect region restoring morphology of mandible.  
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Figure 6a: Specimen 805A – rhBMP-7 solo. Lateral view of right hemimandible with 
reconstruction plate almost completely covered by bone regenerate. Regenerate overgrowth 
beyond the lower border of the mandible.  
 
 
Figure 6b: Specimen 805A – rhBMP-7 solo. Inferior view showing bucco-lingual dimensions 
exceeding adjacent native mandible dimension. 
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Figure 7a: Specimen 816 – rhBMP-7 + rhTGF3. Lateral view of resected right hemimandible 
with reconstruction plate covered by bone regenerate. Decreased alveolar height in area of 
regenerate.  
 
 
 
Figure 7b: Specimen 816 – rhBMP-7 + rhTGF3. Occlusal view showing bucco-lingual 
dimension similar to the adjacent native mandible. 
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Figure 8a: Specimen 811 – rhBMP-7 + rhTGF3. Lateral view of right hemimandible with 
reconstruction plate at the lower border covered by bone regenerate and no evidence of erstwhile 
defect.  
 
 
Figure 8b: Specimen 811 – rhBMP-7 + rhTGF3. Lingual view of resected right hemimandible.   
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Figure 9: Specimen 005 – rhBMP-7 solo. Sagittal section through right hemimandible showing 
high density of bone regenerate. 
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4.2 Qualitative Radiographic analysis 
 
Assessment of radiographic images was qualitative and considered bone volume, visibility of 
interface, and trabecular architecture. In all four specimens the defect margins were 
imperceptible, confirming complete remodelling and integration of the regenerate with the 
recipient bone. The newly formed bone was isodense (in some cases hyperdense) to the normal 
mandible (Figures 10-13). The radiographic appearance of all specimens was uniform throughout 
the defect area, with no areas of radiolucency noted to indicate poor bone formation or density. 
Cortical continuity was evident both on the buccal and lingual borders of the mandible, with no 
steps, breaks or radiolucency noted on either aspect of all four specimens. The trabecular 
architecture was indistinguishable from normal mandible confirming restitutio ad integrum of 
regenerated bone.  Results thus confirm the achievement of “clinically significant 
osteoinduction” as the quality of the regenerated bone is identified radiographically as normal 
bone both in radiodensity and trabecular architecture.
54
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Figure 10a: Specimen 005 - BMP-7 solo. Lateral view of right hemimandible revealing loss of 
margins, isodense regenerate area, trabecular morphology similar to adjacent mandible, and 
restitution of volume within defect.  
 
 
 
 
Figure 10b: Specimen 005 - BMP-7 solo. Occlusal view showing restored bucco-lingual 
dimensions with isodense bone regenerate within defect. 
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Figure 11a: Specimen 805 - BMP-7 solo. Lateral view showing exuberant growth of regenerate 
at the lower border. The regenerate area appears more radiodense than the native mandible.  
 
 
 
Figure 11b: Specimen 805 - BMP-7 solo. Superior view with increased bucco-lingual dimension. 
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Figure 12a: Specimen 811 - BMP-7 + TGF-3. Lateral view right hemimandible with 
imperceptible defect margins and contiguous trabeculae.  
 
 
 
 
Figure 12b: Specimen 811 - BMP-7 + TGF-3. Occlusal view showing increased bucco-lingual 
dimensions with hyperdense bone regenerate. 
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Figure 13: Specimen 816 - BMP-7 + TGF-3. Lateral view showing decreased alveolar height 
but bone regenerate isodense. 
 
 
 
 
 
42 
 
4.3 Histomorphometry 
 
Representative photomicrographs of sagittal histological sections at 5x magnification are shown 
in figures 14-17a through each specimen. Low power histology confirms regeneration with 
highly mineralized bone trabeculae. Trabecular density is greater than the adjacent normal 
mandible. The superior and inferior cortical plates are restored. Bone formation can be seen 
along the recipient margins with more delicate mineralizing trabeculae of woven bone towards 
the centre of the previous defect area. High power magnification (10x) shows newly formed 
trabecular bone facing vascularised marrow with adipose tissue. Osteoblasts can be seen along 
the margin of woven bone (Figures 18a & b).  
 
In specimen 005 implanted with rhBMP-7 solo, the mean amount of new bone formation within 
the defect was 229.1 ± 12.7 mm
2
 (range 220-238mm
2
), which is 43 ± 4.9% (range 40-47%) of 
the regenerate area, and 40.5 ± 6.4% (range 36-45%) of the total defect area. Thus the 
mineralised tissue occupied 43% of the total area of regenerate and 40.5% of the original defect 
area. In specimen 805 implanted with rhBMP-7 solo, the mean amount of new bone formation 
within the regenerate is 444.7 ± 68.7 mm
2
 (range 396-493mm
2
) which is 50.7 ± 7.8% (range 45-
56%) of regenerate, and 48.5 ± 3.5% (range 41-56%) of the original defect area. In specimen 811 
implanted with rhBMP-7 and rhTGF-, the mean amount of new bone formation is 376.6 ± 
68.6mm
2
 (range 328-425mm
2
) which is 53.3 ± 4.9% (range 50-57%) of regenerate area, and 48.9 
± 4.9% (range 45-52%) of the total defect area. In specimen 816 also implanted with rhBMP-7 
and rhTGF-, the average amount of new bone formation is 249.0 ± 22.6mm
2
 (range 233-
43 
 
265mm
2
) which is 73.3 ± 7.1% (range 68-78%) in regenerate area, and 57.3 ± 7.1% (range 52-
62%) of the total defect area (Table 1).  
IMPLANT 
DEVICE 
Bone area in 
regenerate (mm
2
) 
 Mean ± SD 
(Range) 
ROI 1 * (%) 
Mean +/- SD 
(Range) 
ROI 2 **(%) 
Mean +/-SD 
(Range) 
 
BMP-7 SOLO – 005 229.0 ± 12.7 
(220-238) 
43.0 ± 4.9 
(40-47) 
40.5 ± 6.4 
(36-45) 
BMP-7 SOLO – 805  444.7 ± 68.7 
(396-493) 
50.7 ± 7.8 
(45-56) 
48.5 ± 3.5 
(41-56) 
BMP 7 + TGF-3 – 811 376.6 ± 68.6 
(328-425) 
53.3 ± 4.9 
(50-57) 
48.9 ± 4.9 
(45-52) 
BMP 7 + TGF-3 – 816  249.0 ± 22.6 
(233-265) 
75.3 ± 7.1  
(68-78) 
57.3 ± 7.1 
(52-62) 
 
Table 1: Mineralised bone areas  
 
*Percentage of regenerate area consisting of mineralised bone 
**Percentage of original defect area consisting of mineralized bone  
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Figure 14: Specimen 005 – rhBMP-7 solo. Photomicrograph of undecalcified sagittal section 
stained with Goldner’s trichrome (5x).    
 
 
Figure 15: Specimen 805 BMP-7 solo. Photomicrograph through undecalcified sagittal section 
stained with a Goldner’s trichrome (5x). Regenerated tissue shows higher trabecular bone 
density than the native mandible.  
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Figure 16: Specimen 811 BMP-7 + TGF-3. Photomicrograph through undecalcified sagittal 
section stained with a Goldner’s trichrome (5x). Cortical regeneration and increased trabecular 
density within the defect.  
 
Figure 17: Specimen 816 BMP-7 + TGF-3. Photomicrograph through undecalcified sagittal 
section stained with a Goldner’s trichrome (5x). Exceptional bone density within defect area.  
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Figure 18a: Specimen 805 - BMP-7 solo. High power photomicrograph (10x) through 
undecalcified sagittal section stained with a Goldner’s trichrome. Newly formed trabecular bone 
faces vascularized marrow with adipose tissue. Arrow 1: Mineralized tissue, arrow 2: osteoblasts 
visible along margins of bone, arrow 3: adipose tissue.     
 
Figure 18b: Specimen 805 - BMP-7 solo. High power photomicrograph (10x) through 
undecalcified sagittal section stained with a Goldner’s trichrome. Osteoblasts visible along 
margin of mineralised bone (arrow).     
 
1
1
1
2
2
1 
2
1
1
2
2
1 
3
2
1 
47 
 
5 Limitations 
 
The small number of animals available for the study was a significant limitation. With only two 
animals in each study group, it was not possible to identify differences between the treatment 
groups. The lack of a control group is another limitation, however given the scarcity of animals 
available for scientific research, and that previous work in calvaria confirmed that defects of 
2.5cm in diameter do not heal spontaneously, it was decided that a control group was 
unnecessary, since a 2.5cm segmental defect in the mandible is a non-healing defect. Within the 
limit of the study however, binary application of BMP-7 and TGF-3 (ratio of 20:1) showed 
significant restitution of integrity as evaluated histologically and radiographically (Figures 10-
18), but above all, superb morphological healing with substantial bone regeneration and 
cortication of the newly formed segment of the mandibular defect with superior bone density 
across the treated defect area (Figures 5-9).   
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6 DISCUSSION 
 
This study found that all the implanted devices regenerated bone and restituted the osseous micro 
and macro anatomy of the treated mandibular defect. Comparing the area of bone regenerate in 
all four specimens, specimen 805 implanted with rhBMP-7 solo produced the largest area of 
bone regenerate within the defect. Following this was specimen 811 which was implanted with 
rhBMP-7 and rhTGF-3.  Specimen 816 (rhBMP-7 and rhTGF-3) had bone areas slightly lower 
than 811, and the least amount of bone was produced in specimen 005 which was implanted with 
rhBMP-7 solo. Specimen 816 was volumetrically deficient but the density of the regenerate was 
significantly higher in this specimen than all others. This small study failed to identify a 
difference in bone regeneration between the two treatment groups.  
 
Many studies have used histology as the arbitrate of success or failure. The contention of this 
study is that radiography is a far more important tool to assess whether a regenerate has achieved 
preclinical success. High power histology demonstrating new bone formation is often used to 
erroneously conclude success. Although histology is a useful adjunct, it often hides the bone 
architecture, density and mineralization where high power images are zoomed in on only small 
areas of bone formation. Radiographic examination of the entire defect provides unequivocal 
evidence of mineralized tissue regeneration within a defect, the volume of tissue regenerated, the 
amount of remodelling that has occurred (thus resulting in the loss of an obvious defect 
interface) and finally the restitution of the micro anatomical structure of osseous trabeculation.  
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The assessment of all specimens was subjective and qualitative to replicate the clinical scenario 
of bone graft assessment. This confirmed that new bone regeneration had occurred within the 
mandible defects. The bone was isodense to the adjacent normal bone indicating good 
regenerated bone quality. Remodelling was so extensive that the defect margins had become 
imperceptible. The main difference between the various specimens was that of the bone height 
within the defect, where specimen 805 showed greatest bone height, followed by 811 and 005, 
with 816 having the lowest levels of bone height. Although the bone height of 816 was lowest, 
this specimen defect appeared to be most radiopaque. These results were supported by the 
histomorphometry analysis. Finally trabecular morphology is a final confirmation of remodelling 
and once again the regenerate was indistinguishable from the adjacent mandible.  
 
The results of the study have reconfirmed that the morphogens of the TGF- superfamily 
regenerate tissue within surgically created defects that is histologically identifiable as 
mineralized bone. More telling is the radiographic assessment which shows outstanding restitutio 
ad integrum of the surgically created defect. This allows us to conclude that clinically significant 
osseoinduction has been achieved.    
 
Binary application of osteoinductive growth factors has previously shown to significantly 
increase the volume of bone regenerate in orthotopic and heterotopic sites (calvarium) of non-
human primates.
24, 26 
 In this small study no performance advantage was found between the 
single morphogens and binary treated defects, beside the radiographic and histomorphometric 
examinations as outlined under the limitations of the study. 
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A final fundamental question still remains: Are these results translatable into successful therapy 
for human patients? It is becoming clear that this may not be the case as previous attempts at 
therapeutic osseoinduction in humans have shown. Although described as clinically successful 
by its author, critical examination of published radiographic evidence (Figure 1) cannot support 
this contention. Moreover, increasing concern regarding efficacy and safety of Infuse (rhBMP-2) 
raised in several articles by Spine Journal
50
, led to a 16 month investigation into Medtronic 
(Medtronic Inc., Minneapolis, U.S.A.) the makers of Infuse. This investigation found 
questionable ties between the company and the physician consultants commissioned with testing, 
reviewing and reporting on Medtronic products. From this investigation by the Senate Finance 
Committee, it was found that the studies published by Medtronic were inaccurately representing 
the risks of InFuse in addition to placing added weight on alternative treatment side effects. 
Medtronic was found in violation of the trust of patients in their medical care and as a result 
sullied the reputation of bone inductive agents.
55
     
 
Resolving these challenges will require renewed vigour and courage on the part of scientists, 
physicians, patients, and regulatory authorities.  
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7  CONCLUSION 
 
The osteogenic proteins of the TGF- superfamily, solo or in combination, regenerate osseous 
defects of the mandible in Papio ursinus. Qualitative assessment of the regenerate reveals that 
clinically significant osteoinduction has been achieved.  
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